ArticleNeuro-oncology advances
An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Individualized prediction of survival after brain metastasis development in patients with breast cancer.Journal of neuro-oncology · 2026Article
- Individualized prediction of brain metastasis risk in patients with breast cancer.Journal of neuro-oncology · 2026Article
- Deep learning model outperforms traditional models in clinical data-based prognostic prediction for adult-type diffuse glioma.Discover oncology · 2025Article
- Sex-Based Differences in Outcomes for Glioblastoma Patients Treated with Hypofractionated Chemoradiotherapy.Cancers · 2025Article
- Construction and validation of a prognostic nomogram model integrating machine learning-pathomics and clinical features in IDH-wildtype glioblastoma.Journal of translational medicine · 2025Article
- Personalized prognosis stratification of newly diagnosed glioblastoma applying a statistical decision tree model.Journal of neuro-oncology · 2024Article
- Variable screening and model construction for prognosis of elderly patients with lower-grade gliomas based on LASSO-Cox regression: a population-based cohort study.Frontiers in immunology · 2024Article
- Prognostic nomogram models for predicting survival probability in elderly glioblastoma patients.Journal of cancer research and clinical oncology · 2023Article
- Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma.Heliyon · 2023Article
- A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma.Scientific reports · 2023Article
- Perfusion MR prior to radiotherapy is a strong predictor of survival in high-grade gliomas after proton and carbon ion radiotherapy.Annals of translational medicine · 2022Article
- Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.Journal of neuro-oncology · 2021Article
- GLIMPSE: a glioblastoma prognostication model using ensemble learning-a surveillance, epidemiology, and end results study.Health information science and systems · 2021Article
- A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.BMC surgery · 2021Article
- The Influence of Gene Aberrations on Survival in ResectedCurrent oncology (Toronto, Ont.) · 2021Article
- A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.Neuro-oncology · 2021Article
- Deep learning applications in neuro-oncology.Surgical neurology international · 2021Article
- Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study.Neuro-oncology advances · 2020Article
- A Nomogram Predicts Individual Prognosis in Patients With Newly Diagnosed Glioblastoma by Integrating the Extent of Resection of Non-Enhancing Tumors.Frontiers in oncology · 2020Article
- A Comparison Study of Machine Learning (Random Survival Forest) and Classic Statistic (Cox Proportional Hazards) for Predicting Progression in High-Grade Glioma after Proton and Carbon Ion Radiotherapy.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundIn 2016, the World Health Organization reclassified the definition of glioblastoma (GBM), dividing these tumors into isocitrate dehydrogenase (IDH)-wild-type and IDH-mutant GBM, where the vast majority of GBMs are IDH-wild-type. Nomograms are useful tools for individualized estimation of survival. This study aimed to develop and independently validate a nomogram for IDH-wild-type patients with newly diagnosed GBM.
methodsData were obtained from newly diagnosed GBM patients from the Ohio Brain Tumor Study (OBTS) and the University of California San Francisco (UCSF) for diagnosis years 2007-2017 with the following variables: age at diagnosis, sex, extent of resection, concurrent radiation/temozolomide (TMZ) status, Karnofsky Performance Status (KPS), O
resultsA final nomogram was validated for IDH-wild-type newly diagnosed GBM. Factors that increased the probability of survival included younger age at diagnosis, female sex, having gross total resection, having concurrent radiation/TMZ, having a high KPS, and having
conclusionsA nomogram that calculates individualized survival probabilities for IDH-wild-type patients with newly diagnosed GBM could be useful to physicians for counseling patients regarding treatment decisions and optimizing therapeutic approaches. Free software for implementing this nomogram is provided: https://gcioffi.shinyapps.io/Nomogram_For_IDH_Wildtype_GBM_H_Gittleman/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.